The First Innovation in Treatment of Low Testosterone in Men Since 1930th
Acesis Biomed, a biotechnology company based in the US and the UK, is developing an innovative solution for the treatment of low testosterone in men in over 80 years.
Low testoterone (T) in men [hypogonadism] is a condition in which the testicular cells do not produce enough of the hormone T that is essential in masculine growth and pubertal development. As males age, there is a natural decline of T levels after age 30 and continues (about 1% drop per year) throughout their life. The decrease of T levels is often accompanied by erectile dysfunction, decreased muscle mass, osteoporosis, fatigue and mental fogginess, decreased libido and it may predispose men to obesity, insulin resistance and hypertension. There are many other potential causes of low testosterone other than the natural decline, including: testicular trauma, chemotherapy treatments, kidney failure, HIV, opioid or alcohol abuse, obesity, diabetes type 2, Klinefelter syndrome (a genetic condition in which a male is born with an extra copy of the X chromosome), head injury etc.
Hypogonadism affects up to 40% of the world’s adult male population and approximately 20% among men aged 15-39 years. Although testosterone-replacement therapy (TRT) is available for the treatment of hypogonadism, there are undesired side-effects.
Since 2014/2015 TRTs have been labelled by FDA with a ‘black box warning’ informing patients and health care professionals of potential negative side effects. In addition, there is lack of sector innovation with all current therapies being based on the same core steroid technology developed in the 1930s, modified to reduce toxicity or administered through various routes.
Acesis Biomed is unique in its approach as it is developing a “first-in-class”, non-steroidal oral peptide therapeutic which is designed to induce endogenous testosterone production in testosterone-deficient males. By instructing the body’s Leydig cells in the testis to produce testosterone naturally, Acesis aims to provide a safe, effective, and accessible treatment which will also tackle the patent cliff set to rock the industry in the next 6-8 years. In the simplest terms, Acesis Biomed's products is expected to have a superior safety profile compared to existing treatments and change the standard of care for hypogonadism and related co-morbidities.
We caught up with Costas Karatzas, CEO, director and co-founder of Acesis Biomed to learn more.
Continue reading
This content available exclusively for BPT Mebmers
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.
